X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (33) 33
male (23) 23
female (22) 22
abridged index medicus (19) 19
medicine, general & internal (19) 19
aged (15) 15
middle aged (15) 15
cardiovascular disease (14) 14
mortality (11) 11
risk (11) 11
stroke (11) 11
double-blind method (10) 10
drug therapy (10) 10
health risk assessment (10) 10
cardiovascular diseases - prevention & control (9) 9
clinical trials (9) 9
prevention (9) 9
dermatology (8) 8
disease prevention (8) 8
incidence (8) 8
risk factors (8) 8
cardiovascular diseases (7) 7
cholesterol (7) 7
heart attacks (7) 7
myocardial infarction (7) 7
aspirin (6) 6
atherosclerosis (6) 6
cardiovascular diseases - mortality (6) 6
care and treatment (6) 6
drug therapy, combination (6) 6
myocardial-infarction (6) 6
treatment outcome (6) 6
acute coronary syndromes (5) 5
analysis (5) 5
australia (5) 5
cerebral infarction (5) 5
coronary-heart-disease (5) 5
dosage and administration (5) 5
dose-response relationship, drug (5) 5
eczema (5) 5
heart diseases (5) 5
inflammation (5) 5
low density lipoprotein (5) 5
metaanalysis (5) 5
patients (5) 5
statins (5) 5
adult (4) 4
blood pressure (4) 4
c-reactive protein (4) 4
cancer (4) 4
cardiac & cardiovascular systems (4) 4
cardiovascular diseases - epidemiology (4) 4
cardiovascular-disease (4) 4
child (4) 4
cholesterol, ldl - blood (4) 4
coronary vessels (4) 4
disease (4) 4
infant (4) 4
myocardial infarction - epidemiology (4) 4
myocardial infarction - prevention & control (4) 4
prospective studies (4) 4
rivaroxaban (4) 4
rosuvastatin (4) 4
secondary prevention (4) 4
skin (4) 4
statin therapy (4) 4
stroke - prevention & control (4) 4
studies (4) 4
therapy (4) 4
adolescent (3) 3
angina pectoris (3) 3
arteriosclerosis (3) 3
aspirin - adverse effects (3) 3
aspirin - therapeutic use (3) 3
asthma (3) 3
atherosclerosis - drug therapy (3) 3
benzimidazoles - administration & dosage (3) 3
case-control studies (3) 3
child, preschool (3) 3
children (3) 3
clopidogrel (3) 3
disease control (3) 3
epidemiology (3) 3
factor xa inhibitors - adverse effects (3) 3
factor xa inhibitors - therapeutic use (3) 3
heart attack (3) 3
hemorrhage (3) 3
hemorrhage - chemically induced (3) 3
hydrochlorothiazide - administration & dosage (3) 3
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (3) 3
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (3) 3
infant, newborn (3) 3
journal article (3) 3
left-ventricular dysfunction (3) 3
life sciences (3) 3
lipids (3) 3
lipoproteins (3) 3
low density lipoproteins (3) 3
management (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus | Klinisk medicin | Clinical Medicine
Journal Article